glp 1 parkinson's The Emerging Role of GLP-1 RAs in Disease GLP-1 Drugs and Parkinson's Disease:

D.HolstA

53 OKeeffeG.HammelS.OwensR

For the MIA short-term study, mice received a single IA injection of liraglutide (1, 5, 10, or 20 g) or empty vehicle (5 L) into the right knee on day 3

doi: 10.1016/j.arr.2007.04.004

External resources PMC: The physiology of weight loss plateaus during obesity pharmacotherapy , a comprehensive analysis of metabolic adaptation mechanisms during GLP-1 receptor agonist therapy, including appetite feedback coefficients and energy expenditure changes

Unlike GLP-1 agonists that reduce appetite or growth hormone peptides that stimulate lipolysis, the compound addresses fat metabolism at the enzymatic level: it removes the molecular governor that locks adipocytes into a low-energy-expenditure state, potentially restoring normal metabolic function in fat tissue where NNMT is overexpressed